-
Bank Of America: What To Expect For Rite Aid Ahead Of FTC Merger Decision
Wednesday, June 28, 2017 - 11:46am | 406Read More...Rite Aid Corporation (NYSE: RAD) stock has been all over the radar since its proposed merger with Walgreens Boots Alliance Inc (NASDAQ: WBA) was announced in October of 2015. Rite Aid’s stock has been at the mercy of media rumors about whether the Federal Trade Commission will allow the...
-
McKesson Has A Lot Of Moving Parts; Bank Of America Reinstates At Neutral
Tuesday, June 7, 2016 - 1:22pm | 310Read More...Bank of America analysts Steven Valiquette and Jonathan Yong see a lot of moving parts in McKesson Corporation (NYSE: MCK) in the areas of generic pricing and customers. As a result, the two analysts have reinstated the stock at Neutral with a price objective of $190.00 on the shares of the company...
-
Cerner's First Bookings Miss Since '08 Has Analysts Mixed
Thursday, February 18, 2016 - 9:47am | 452Read More...The market punished healthcare information technology supplier Cerner Corporation (NASDAQ: CERN) Wednesday after the company reported a fourth-quarter bookings miss in a quarterly report issued at market close Tuesday. The company missed a bookings benchmark with $1.35 billion, falling short of its...
-
UBS Says Take Advantage Of Recent Weakness In Patterson; Upgrades To Buy
Thursday, January 28, 2016 - 10:50am | 336Read More...UBS issued a company note on Patterson Companies, Inc. (NASDAQ: PDCO) after the UBS Global Dental Survey was released, suggesting industry growth in the United States can accelerate in 2016. UBS upgraded Patterson Companies from Neutral to Buy and raised their price target from $49 to $50. "...
-
Analyst: Cardinal Health Buying Spree To Boost FY17 EPS
Tuesday, June 9, 2015 - 12:23pm | 267Read More...Cardinal Health Inc (NYSE: CAH)'s recent pair of billion-dollar-plus acquisitions should boost its earnings growth in the year ending June 2017, an analyst said Tuesday. UBS's Steven Valiquette boosted his price target about 2 percent to $97, maintaining a Buy rating on the drug...
-
The 3 Biggest Questions Facing Walgreens
Tuesday, April 7, 2015 - 11:10am | 511Read More...In a report published Tuesday, UBS analyst Steven Valiquette offered three important questions Walgreens Boots Alliance Inc (NASDAQ: WBA) investors should be aware of ahead of the company's analyst meeting on April 15-16. How Can Management Expand U.S. Margins In Current Environment?...
-
UPDATE: UBS Securities Downgrades Patterson Companies on F2Q14 Preview and Valuation Update
Wednesday, November 20, 2013 - 10:35am | 157Read More...In a report published Wednesday, UBS Securities analyst Steven Valiquette downgraded the rating on Patterson Companies (NASDAQ: PDCO) from Buy to Neutral, but reiterated the $46.00 price target. In the report, UBS Securities noted, “Based on strong U.S. trends from dental/vet peers, and a much...
-
UPDATE: UBS Investment Research Raises PT on Cardinal Health Following F4Q13 Conference Call
Friday, August 2, 2013 - 10:52am | 127Read More...In a report published Friday, UBS Investment Research analyst Steven Valiquette reiterated a Buy rating on Cardinal Health (NYSE: CAH), and raised the price target from $53.00 to $58.00. In the report, UBS Investment Research noted, “In our view, a key takeaway from the CAH F4Q13 conf call is...
